Shield Therapeutics Eyes Expansion in Korea
Company Announcements

Shield Therapeutics Eyes Expansion in Korea

Shield Therapeutics (GB:STX) has released an update.

Shield Therapeutics’ partner, Korea Pharma, has filed a New Drug Application for the iron deficiency treatment Accrufer® in South Korea, with approval expected in 2025. This marks a significant step toward expanding Accrufer®’s global reach, following a successful local pharmacokinetic study confirming its efficacy. Shield Therapeutics stands to receive milestone payments and royalties on Korean sales, while also handling initial manufacturing and supply.

For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskShield Therapeutics Sees Revenue Surge and Financial Boost
TipRanks UK Auto-Generated NewsdeskShield Therapeutics’ Pediatric IDA Trial Succeeds
TipRanks UK Auto-Generated NewsdeskShield Therapeutics Sees Strong Revenue Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App